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INTRODUCTION
As in normal prostate, the survival 
and growth of prostate cancer (PCa) cells
also is driven by androgens. Therefore,
androgen- deprivation therapy is the first-
line treatment for clinically advanced PCa
(1). Despite medical or surgical castration,
in most of the patients, cancer recurs and
may be considered as castration resistant
prostate cancer (CRPC) (2). There are sev-
eral proposed mechanisms leading to this
incurable state of disease. Among others,
the presence of cancer-initiating cells that
are independent from androgens for their
self-renewal, as well as the ability of PCa
tissue to synthesize testosterone (T) and
dihydrotestosterone (DHT) has been pos-
tulated (reviewed in 3).
Surgical and pharmacological andro-
gen deprivation therapy aims to lower
the amount of circulating testosterone.
Secondary endocrine therapies are aimed
to inhibit ligand binding to the androgen
receptor (AR) with antiandrogens. How-
ever, several studies have confirmed that
there are still sufficient amounts of T and
DHT in the prostatic tissue to activate
AR and its target genes that drive cancer
cell survival and proliferation (4–8) even
in the presence of the currently approved
antiandrogens. Additionally, castration
has little effect on the levels of adrenal
androgens dehydroepiandrosterone
(DHEA), its sulfate (DHEA-S) and
 androstenedione, by reducing them only
40% to 50% (4,7).
Androgen sensitivity of CRPC is
demonstrated clearly by the fact that re-
current tumors respond to additional en-
docrine therapies (9,10). Several recent
studies have reported upregulation of
steroidogenic enzymes in CRPC which
could lead to androgen production from
adrenal androgens, and explain the lev-
els of DHT and T found in prostate tis-
sue (11–13). Moreover, there is evidence
for de novo steroidogenesis from choles-
terol by PCa cells (14). Supporting this
observation, enzymes in the cholesterol
biosynthesis pathway have shown to be
upregulated in CRPC (15). Additionally,
a number of studies provide evidence for
stemlike cells that may be the initiating
population for a recurrent tumor in PCa
(16–20). Whether adaptation to low an-
drogen levels is initiated by PCa stem
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cells or by altering intracellular steroid
metabolism is not yet known.
In this study, we compared the ex-
pression of steroidogenic enzymes in
clinical samples of different stages of
PCa and in the DuCaP cell line model.
Many steroidogenic enzymes are upreg-
ulated in castration settings. In vitro
these cells are enriched for some puta-
tive stem cell markers. Many stem cell
markers are upregulated as well in clini-
cal CRPC. This is the first evidence that
links steroidogenesis with cancer-
 initiating cells in PCa.
MATERIALS AND METHODS
Patient Characteristics and Tissue
Collection
Samples were collected at the Rad-
boud University Nijmegen Medical Cen-
tre in 1987–2008, and the use was ap-
proved by the local ethical committee.
On the basis of the pathology findings
and the case records, patients were di-
vided into four different groups: low
grade PCa (LG, n = 20), high grade PCa
(HG, n = 22), castration- resistant PCa
(CRPC, n = 21) and metastatic PCa (met,
n = 7) (Table 1). Castration-resistant sta-
tus is defined as patients who failed con-
ventional hormonal therapy. Upon radi-
cal prostatectomy, transurethral resection
of the prostate or lymph node dissection,
specimens were snap frozen in liquid ni-
trogen. Tissues were selected by micro-
scopic assessment for purity of cancer
cells and processed by step sectioning.
RNA Isolation
Total RNA was extracted from tissue
sections by using Trizol reagent (Invitro-
gen, Carlsbad, CA, USA). RNA was
DNase treated and purified by using the
RNeasy Mini Kit (Qiagen, Venlo, the
Netherlands) according to manufacturer’s
instructions. RNA purity was determined
by using Agilent 2100 bioanalyzer and
 Agilent RNA 6000 Nano kit (Agilent Tech-
nologies, Santa Clara, CA, USA). Only
samples with RIN (RNA Integrity Num-
ber) of >6 were included for microarray
analysis.
Expression Analysis
Gene expression profiles were deter-
mined by using Affymetrix GeneChip 1.0
Human Exon ST (Affymetrix, Santa Clara,
CA, USA) arrays according to manufac-
turer’s instructions. Affymetrix GeneChip
Whole Transcript Sense Target Labeling
Assay (Affymetrix) was used to generate
amplified and biotinylated sense-strand
DNA targets from the entire expressed ge-
nome without bias. RNeasy purified total
RNA (1 μg) was used, and an rRNA reduc-
tion step was included by using RiboMinus
Human/Mouse Module  (Invitrogen).
After hybridization by rotation at 0.33g
in the Affymetrix GeneChip hybridization
oven at 45°C for 16 h, arrays were washed
in Affymetrix GeneChip Fluidics station
FS 450, and scanned by using Affymetrix
Gene Chip scanner 3000 7G system
(Affymetrix). Gene- and exon-level ex-
pression signal estimates were derived
from CEL files generated from Affymetrix
GeneChip Exon 1.0 ST arrays by using
multiarray analysis algorithm imple-
mented from Affymetrix Power Tools
software (Affymetrix). Gene-level esti-
mates were obtained by using the “core”
metaprobe list annotation release 21.
In Vitro Cultures
DuCaP cell line was kindly provided
by Ken Pienta (University of Michigan,
Ann Arbor, MI, USA). Cells were grown
in RPMI-1640 supplemented with 10%
fetal calf serum (FCS) (Sigma-Aldrich, St.
Louis, MO, USA). Ten percent of char-
coal-stripped serum (CSS) was used in-
stead of FCS when culturing cells under
hormone depletion. The used passage
numbers were 39–49.
Real-Time PCR
Two micrograms of Trizol-isolated
total RNA was DNase treated, and
cDNA was synthesized by using ran-
dom primers (hexamers) and Super-
script II Reverse Transcriptase (Invitro-
gen). Gene expression was determined
by using SYBR Green PCR mix (Roche)
and 10 ng of template. Real-time PCR
was performed on a LightCycler LC480
instrument (Roche, Basel, Switzerland),
using the following amplification condi-
tions: 5 min at 95°C; followed by 50 cy-
cles of 10 sec at 95°C; 20 sec at 60°C and
20 sec at 72°C. Cp- values were deter-
mined by using the LightCycler 480 SW
1.5 software (Roche). The primers were
designed with OligoPerfect Designer
(Invitrogen) or taken from a previous
publication by Locke et al. (14) or Mont-
gomery et al. (12). Primer sequences are
listed in the Supplementary Table 1.
Gene expression in each sample was
normalized with the housekeeping gene
(β2-microglobulin) expression. Assays
were performed three times.
Cell Viability
Cells were seeded on 96-well plates
(Corning Incorporated, Corning, NY,
USA) 6,000 cells/ well in RPMI-1640
supplemented with 10% FCS or CSS.
Half of the medium was changed 
every fourth day. A standard MTT
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Table 1. Patient characteristics.
Group LG HG met CRPC
Number of patients 20 22 7 21
Previous treatment none none none surgical or medical
castration with or 
without antiandrogens
Site of metastasis N/A N/A LN (n = 6) N/A
testis (n = 1)
Gleason score 4 (n = 6) 7 (n = 3) N/A N/A
5 (n = 4) 8 (n = 11)
6 (n = 10) 9 (n = 3)
10 (n = 5)
N/A, not applicable; LN, lymph node.
(MethylThiazolyldiphenyl-Tetrazolium
bromide, Sigma-Aldrich) assay was per-
formed up to 24 d. Experiments were re-
peated three times with triplicates.
Immunocytochemistry
Cells were grown for 7 d on glass
slides or on collagen I coated slides for
α2-integrin staining, and fixed with ice
cold acetone for 10 min or with 4%
paraformaldehyde at RT for 10 min. Ace-
tone-fixed cells were stained with mono-
clonal antibodies; CK18 (clone DC10,
DAKO), cytokeratin 5 (CK5) (clone
RCK103, Euro- Diagnostica, Malmö, Swe-
den), BCRP (Millipore, Billerica, MA,
USA), CD49b (α2-integrin, clone Gi-14;
from S Santoso, Giessen, Germany), and
with the polyclonal antibody c-kit
(A4502, Dako, Glostrup, Denmark). The
4% paraformaldehyde-fixed cells were
stained with CD133/2 (Miltenyi Biotec,
Bergisch Gladbach, Germany) and nestin
(Millipore). CK18 (1:100), CK5 (1:2),
R E S E A R C H  A R T I C L E
M O L  M E D  1 7 ( 7 - 8 ) 6 5 7 - 6 6 4 ,  J U L Y - A U G U S T  2 0 1 1  |  P F E I F F E R E T  A L .  |  6 5 9
Figure 1. Schematic overview of the steroidogenic pathway. AMACR, α-methylacyl-CoA racemase; FASN, fatty acid synthase; SREB, G
protein-coupled receptor; StAR, steroidogenic acute regulatory protein; CYP, cytochrome P450; CYB5, cytochrome b5; HSD, hydroxys-
teroid dehydrogenase; AKR, aldo-keto reductase; SRD, 5α-reductase; UGT, UDP glucuronosyltransferase; green boxes, adrenal androgens;
blue box, testicular androgen; yellow box, tissue androgen.
CD49b (1:400), c-kit (1:200), and
CD133/2 (1:200 dilution) were incubated
for 1–2 h at RT and antibodies against
nestin (1:200) and BCRP (1:100)
overnight at 4°C. Powervision poly-HRP-
goat antimouse/rabbit/ rat IgG (Im-
munoLogic, Duiven, the Netherlands)
was used as the secondary antibody. Ex-
cept in the case of c-kit, where goat-an-
tirabbit secondary antibody RPN1004V1
(1:200, GE Healthcare, Buckinghamshire,
UK) was used with subsequent incuba-
tion with Vectastain ABC-peroxidase so-
lution (Vector, Burlingame, CA, USA).
Detection of antibody binding was per-
formed by using 3,3′-diaminobenzidine
(Power DAB, ImmunoLogic) to observe
peroxidase activity. The nuclei were
counterstained with hematoxylin.
Known positive tissues or cells were
used as controls. The staining was stud-
ied under a light microscope. All positive
cells on slides were counted, and the
number of negative cells was estimated
by multiplying the counted cells on rep-
resentative fields by the slide area.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Expression of Steroidogenic Enzymes
Is Altered in Clinical CRPC
The mRNA expression of genes in-
volved in steroid metabolism (Figure 1)
and androgen signaling in patient sam-
ples of LG, HG, met and CRPC were
studied by microarray analysis. Most of
the statistically significant differences in
gene expression appeared in CRPC
(Table 2). Expression values with the
most differences are shown as box plots
in Figure 2. The expression of AR and
steroidogenic enzymes AKR1C3,
HSD17B2, HSD17B3, UGT2B15 and
UGT2B17, was generally upregulated in
CRPC, whereas SRD5A2 was downreg-
ulated. AKR1C3 expression was signifi-
cantly different in CRPC versus LG (P =
0.004). Also the expression levels for
HSD17B2 in CRPC compared with LG
(P = 0.001), HG (P = 0.002) and met (P =
0.001), and for HSD17B3 in met versus
LG (P = 0.049) and HG (P = 0.016), and
CRPC versus LG (P = 0.004) and HG 
(P = 0.024) were significantly different.
SRD5A2 expression was different in
met versus LG and HG, and CRPC
compared with LG, HG and met (P =
0.000, 0.000, 0.000, 0.000 and 0.003, re-
spectively). UGT2B15 expression was
different between CRPC and LG (P =
0.001), and HG (P = 0.032) and met 
(P = 0.001). UGT2B17 was upregulated
in CRPC versus LG (P = 0.001) and HG
(P = 0.023). In addition, the expression
of AR was significantly different in met
versus LG, and in CRPC versus LG, HG
and met (P = 0.000, 0.000, 0.000 and
0.044, respectively).
Expression of Steroidogenic Enzymes
Is Altered in DuCaP during Hormone
Depletion
To examine the expression of
steroidogenic enzymes during short-
term androgen ablation, we cultured
DuCaP cells in medium containing CSS
for 24, 48, 96 h and 12 d. These condi-
tions also were maintained for several
passages to study the long-term effect
of androgen ablation. Only a small
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Table 2. Mean fold-change values in mRNA expression of steroid metabolism/signaling
related genes in clinical samples of LG, HG, met and CRPC.
Gene bank HG met met CRPC CRPC CRPC
accession versus versus versus versus versus versus 
Gene number LGd LG HG LG HG met
FASN NM_004104 0.8 1.1 1.3 1.0 1.2 0.9
StAR NM_000349 1.0 1.5 1.5 1.1 1.1 0.7
CYP11A1 NM_001099773 1.0 1.2 1.2 1.0 1.0 0.9
CYP17A1 NM_000102 1.1 1.2a 1.2 1.1a 1.0 0.9
HSD3B2 BC131488 1.0 1.0 1.0 1.1 1.1 1.0
HSD17B2 NM_002153 1.0 1.0 1.0 1.6b 1.7b 1.7b
HSD17B3 NM_000197 1.1 1.3a 1.2a 1.3b 1.2a 1.0
HSD17B4 NM_000414 1.0 0.8 0.8 0.8 0.8 1.0
HSD17B10 NM_004493 1.0 1.1 1.1 1.0 1.0a 0.9
AKR1C1 NM_001353 2.2 1.3 0.6 2.5a 1.1 1.9
AKR1C2 NM_205845 1.2 1.1 0.9 1.0 0.8 0.9
AKR1C3 NM_003739 1.5 1.6 1.0 2.3b 1.5 1.4
RDH5 NM_002905 1.0 1.1 1.1 1.1 1.1 1.1
SRD5A1 NM_001047 1.0 1.0 1.0 1.1 1.0 1.0
SRD5A2 NM_000348 0.8 0.2b 0.2b 0.3b 0.4b 1.8b
SRD5A3 NM_024592 0.9 1.1 1.1 1.0 1.1 1.0
UGT2B15 NM_001076 1.5 1.4 0.9 2.5b 1.7a 1.8b
UGT2B17 NM_001077 1.2 1.3 1.0 1.7b 1.4a 1.3
AMACR NM_014324 1.2 0.8 0.6 0.6a 0.5 0.7
SREB1 NM_001005291 0.9 1.0 1.1 0.8a 0.8 0.8
SREB2 NM_004599 0.9 1.4a 1.5b 1.0 1.0 0.7b
CYB5A NM_148923 0.8a 0.7a 0.9 0.6a 0.7 0.9
AR NM_000044 1.0 1.7b 1.6 4.1b 4.0b 2.5a
ERG NM_004449 0.7 1.6 2.1 0.7 1.0 0.5
KLK3 NM_001030047 0.7 0.9 1.3 0.6a 0.9 0.7
TMPRSS2 NM_005656 0.5a 0.5 1.0 0.8b 1.6 1.6
FASN, fatty acid synthase; StAR, steroidogenic acute regulatory protein; CYP, cytochrome
P450; HSD, hydroxysteroid dehydrogenase; AKR, aldo-keto reductase; RDH, retinol
dehydrogenase (oxidative 3α-HSD); SRD, 5α-reductase; UGT, UDP glucuronosyltransferase;
AMACR, α-methylacyl-CoA racemase; SREB, G protein-coupled receptor; CYB5,
cytochrome b5; ERG, v-ets erythroblastosis virus E26 oncogene homolog; KLK, kallikrein-
related peptidase; TMPRSS2, transmembrane protease, serine 2.
aStatistical analysis: t test. P < 0.05.
bStatistical analysis: t test. P < 0.01.
 subset of cells survived. Finally, within
5 months, a culture adapted to hormone
deficient environment was proliferating,
and could be maintained in these condi-
tions. The mRNA expression of genes
involved in steroid metabolism is up-
regulated in hormone depleted condi-
tions both short term (Figure 3) and
long term (Figure 4). Only HSD17B2
was downregulated in long-term hor-
mone depletion.
Hormone Depletion Surviving Cells
Can Repopulate the Culture after
Hormonal Restoration
Only a small population of DuCaP
cells remained viable during 24 d of hor-
monal depletion, but this population did
not increase in number during the exper-
iment. However, when normal hormonal
conditions were restored, these cells re-
populated the culture (Figure 5).
Hormone Depletion Surviving Cells
Express Putative Stem/Progenitor Cell
Markers
The expression of putative stem/prog-
enitor cell markers was assessed by im-
munocytochemistry in DuCaP. The num-
ber of CK5 and ATP-binding cassette
sub-family G member 2 (ABCG2)-
 expressing cells in hormone-depleted
conditions was 1.3-fold and 14.9-fold
higher, respectively, than in normal con-
ditions. Owing to high standard devia-
tion between experiments, we could not
show statistical significance in the meas-
urements. Most cells in both culture con-
ditions were positive for α2-integrin. No
staining was detected for c-Kit, nestin or
CD133 (Table 3 and Figure 6).
Expression of Putative Stem/Progenitor
Cell Markers Is Upregulated in Clinical
CRPC
We studied the mRNA expression lev-
els of several putative stem/progenitor
cell markers in patient samples from
metastatic PCa and CRPC by microarray.
These samples of pure cancer tissue were
chosen to avoid the effect of possible
presence of normal cells on the expres-
sion values. CK5, c-Kit, nestin, CD44 and
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Figure 2. mRNA expression of AR and enzymes involved in steroid metabolism in clinical
samples of LG, HG, met and CRPC. Analysis was done by using the t test. *P < 0.05; **P <
0.01. Horizontal line, median value; open circle, outliers; small asterisk, extremes. AKR, aldo-
keto reductase; HSD, hydroxysteroid dehydrogenase; SRD, 5α-reductase; UGT, UDP glu-
curonosyltransferase.
Figure 3. Relative expression values of enzymes involved in steroid metabolism and AR
during hormone depletion up to 12 d in DuCaP cells. The mRNA expression of DuCaP cells
grown in RPMI-1640 supplemented with 10% FCS or 10% CSS for 24–96 h and 12 d was as-
sessed by qRT-PCR SYBR Green method. Relative expression values were calculated by
using expression values in basic culture conditions (FCS 24h) as a reference. Enzymes
CYP11A1, CYP17A1, HSD3B2 and HSD17B3, for which the Cp-values were high (Cp > 36),
were left out of the figure. Experiment was done twice. Two-way ANOVA; Error bars, SEM;
*P < 0.05; **P < 0.01. StAR, steroidogenic acute regulatory protein; FASN, fatty acid syn-
thase; HSD, hydroxysteroid dehydrogenase; AKR, aldo-keto reductase; RDH, retinol dehy-
drogenase (oxidative 3α-HSD).
c-Met were upregulated significantly in
CRPC compared with noncastrated clini-
cal metastatic disease (P = 0.000, 0.007,
0.000, 0.036 and 0.018, respectively). A
trend in higher expression of putative
stem cell markers aldehyde dehydrogenase 1
family, member A1 (ALDH1A1), α2-integrin,
CD133, ABCG2 and C-X-C chemokine re-
ceptor type 4 (CXCR4), both POU class 5
homeobox 1 (POU5F1; alternative name
Oct3/4) transcript variants, and lower ex-
pression of α6-integrin, SRY (sex determin-
ing region Y)-box 2 (SOX2) and Nanog
homeobox (Nanog) was  noticed in CRPC,
but without statistical significance.
(Table 4 and Figure 7).
DISCUSSION
Similar to recent studies (11–14), we
show that several steroidogenic enzymes
are upregulated in CRPC. In particular,
the gene expression of the enzymes
(HSD17B2, HSD17B3, AKR1C3, SRD5A2,
UGT2B15 and UGT2B17) of the last steps
in the steroidogenic pathway from adre-
nal androgens to T, DHT and their elimi-
nation to glucuronide derivatives were
changed. Compared to Montgomery et
al. (12) and Hofland et al. (11), we could
not detect a significant upregulation of
SRD5A1 in CRPC. However, the expres-
sion level of SRD5A2 was downregu-
lated, resulting in a possible takeover by
SRD5A1 as the main 5α-reductase. The
activation of the steroid metabolism
 simultaneous toward and away from the
active steroids clearly indicates that this
balance is controlled carefully in the tis-
sue. Like presented by Hofland et al. (11),
the last steps in steroidogenesis seem
pivotal in the adaptation to castrate state.
Therapies targeting these steps of
steroidogenesis may prove to be an im-
portant addition to current endocrine
therapies.
DuCaP is a representative model to
study CRPC, since it expresses wild type
AR, possesses TMPRSS2-ERG transloca-
tion and contains stromal cells. We have
shown previously that endocrine therapy
can be mimicked in vitro by growing
DuCaP cells in CSS. (21) In these condi-
tions, all tested steroidogenic enzymes
are upregulated and become more pro-
nounced in time. Despite the changes in
the steroidogenic pathway, the cells in
hormone-depleted conditions do not pro-
liferate. However, after being subjected
for a long period of time to poor hor-
monal environment, a new cell culture
arose adjusted to these conditions. Previ-
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Figure 5. Proliferation of DuCaP cells in dif-
ferent hormonal conditions. Cells were
grown in RPMI-1640 supplemented with
10% FCS or 10% CSS, or first 12 d with CSS
after which FCS was re-administered the
next 12 d. Cell viability was measured with
a standard MTT assay. The graph shows
optical density values at 595 nm. Experi-
ment was done three times with tripli-
cates. Two-way ANOVA. Line, trend line;
error bars, SEM; **P < 0.01.
Figure 4. Relative expression values of enzymes involved in steroid metabolism and AR
during continuous hormone depletion DuCaP cells. The mRNA expression of DuCaP cells
grown in RPMI-1640 supplemented with 10% FCS or 10% CSS for several passages (P1–P2)
was assessed by qRT-PCR SYBR Green method. Relative expression values were calcu-
lated by using expression values in  hormone-depleted culture conditions (CSS) as a refer-
ence. Enzymes CYP11A1, CYP17A1 and HSD3B2, for which the Cp-values were high (Cp >
36), were left out of the figure. Experiment was done twice. Two-way ANOVA; Error bars,
SEM; *P < 0.05; **P < 0.01. StAR, steroidogenic acute regulatory protein; FASN, fatty acid
synthase; HSD, hydroxysteroid dehydrogenase; AKR, aldo-keto reductase; RDH, retinol de-
hydrogenase (oxidative 3α-HSD).
Table 3. Number of positive DuCaP cells in normal (FCS) and hormone-depleted (CSS)
culture conditions in immunohistochemical stainings for putative stem/progenitor cell
markers.
Marker FCSa,b CSSa,b Fold-change
CK5 0.24% (±0.23) 0.32% (±0.25) 1.3
ABCG2 0.02% (±0.02) 0.28% (±0.32) 14.9
α2-integrin most most —
c-Kit nd nd —
Nestin nd nd —
CD133c nd nd —
aStandard deviation in parentheses.
bnd, not detected.
cCD133, prominin 1.
ously, DuCaP was suggested to contain
stemlike cells (19). Since only a small cell
population survives androgen depletion
in vitro, and is capable to repopulate the
culture, these surviving cells may indeed
be stemlike. Immunostainings for several
stem/progenitor cell markers revealed
an increase in CK5- and ABCG2-express-
ing cells. This observation was extended
to clinical PCa; the gene expression of
many stem cell markers was upregulated
in CRPC compared with nontreated PCa.
Immunohistochemical studies in clini-
cal samples are needed to further validate
the results by us and others, as investiga-
tion on mRNA does not necessarily reflect
the expression level of the protein in ques-
tion. We are currently studying AKR1C3
in CRPC in more depth. Additionally,
studies on hormone levels in DuCaP
would reveal more functional information
about the steroidogenic enzymes as
demonstrated by Locke et al. (14). We ana-
lyzed testosterone and DHT levels in
DuCaP-conditioned hormone-depleted
medium by liquid  chromatography/
radioimmunoassay. Unfortunately with
this method the detection level threshold
was too low (T: 0.02 and DHT: 0.1
nmol/L) to detect any change in metabo-
lism in this type of samples.
We approached the problem of PCa re-
currence after therapy with a novel point
of view by the combination of stemlike
cells and steroid metabolism. The upreg-
ulation of steroidogenic enzymes and
stem cell markers in recurrent tumors
suggests a linkage between steroidogene-
sis and stem cells. As the endocrine ther-
apy targets the androgen sensitive cells
of the tumor, stemlike cells survive the
deprivation. These cells may give rise to
cells that have adapted their androgen
metabolism. The remaining adrenal an-
drogens may then be utilized to restore
the appropriate androgen environment
for the recurrent tumor.
Taken together, enzymes involved in
steroidogenesis are upregulated both in
clinical CRPC and in castration settings
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Figure 6. Immunohistochemical stainings for putative stem/progenitor cell markers in DuCaP.
Cells were grown in RPMI-1640 supplemented with 10% FCS or 10% CSS for 7 d and stained
for putative stem/progenitor cell markers. Positive staining was found for CK5, ABCG2 and
α2-integrin. No staining was detected for c-Kit, nestin or CD133. Known positive tissues or
cells were used as controls. Scale: 0.2 mm.
Table 4. Mean fold-change values in
mRNA expression of putative stem cell
markers in clinical samples.
Gene bank CRPC 
accession versus











POU5F1 variant 1 NM_002701.4 1.1




aStatistical analysis: t test. P < 0.01.
bStatistical analysis: t test. P < 0.05,
cCD133, prominin 1.
Figure 7. mRNA expression of putative stem cell markers in clinical samples of met and
CRPC. Analysis was done by using the t test. Horizontal line, median value; open circle, out-
liers; asterisk, extremes. CD133, prominin 1.
in vitro. Also, an enrichment of stem cell
markers was shown in these samples.
Current endocrine therapies may induce
a selection for stemlike cancer cells and
an induced steroidogenesis. Our results
support the rationale to combine castra-
tion and antiandrogen treatment with
 inhibitors that block adrenal androgen
 metabolism and autocrine steroidogene-
sis in prostate tissue. This may prove to
be a more successful approach to pre-
venting disease progression to CRPC.
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